YX968

Overview

YX968 is a selective HDAC3 / HDAC8 PROTAC dual degrader, with a DC 50 value of 1.7 nM against HDAC3 and 6.1 nM against HDAC8 . YX968 inhibits cancer cell growth, induces apoptosis , prevents global histone hyperacetylation, and exerts effects via antiproliferative activity. YX968 can be used in research related to triple-negative breast cancer , non-small cell lung cancer , and multiple myeloma. (Pink: HDAC3 and hHDAC8 ligand ( HY-168287 ); Blue: VHL ligand ( HY-112078 ); Black: linker ( HY-W007700 )).

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-164233
• CAS No.: 2742732-92-7
• Molecular Formula: C45H66N8O5S
• Molecular Weight: 831.12
• Purity: 98.06%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 5 mg/mL (6.02 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
• Availability: In-stock

Source

Original product source